

# Clinico-Hematological and cytogenetic spectrum of adult myelodysplastic syndrome The first retrospective cross-sectional study in Iranian patients

**Mostafa Paridar**

Iran Ministry of Health and Medical Education

**Kazem Zibara**

Lebanese University: Universite Libanaise

**Seyed Esmaeil Ahmadi**

IUMS: Iran University of Medical Sciences

**Abbas Khosravi**

IBTO: Iranian Blood Transfusion Organization

**Maral Soleymani**

AJUMS: Ahvaz Jondishapour University of Medical Sciences

**Ebrahim Azizi**

AJUMS: Ahvaz Jondishapour University of Medical Sciences

**Omid Kiani Ghalesardi** (✉ [omidkianis@gmail.com](mailto:omidkianis@gmail.com))

IUMS: Iran University of Medical Sciences <https://orcid.org/0000-0002-8939-491X>

---

## Research Article

**Keywords:** Myelodysplastic syndromes, Hematological spectrum, Cytogenetic, Iran

**Posted Date:** March 2nd, 2021

**DOI:** <https://doi.org/10.21203/rs.3.rs-249637/v1>

**License:**   This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

---

# Abstract

## Background

Myelodysplastic syndrome (MDS), a heterogeneous group of hematopoietic malignancy, has been shown to present different cytogenetic abnormalities, risk factors, and clinico-hematological features in different populations and geographic areas. Herein, we determined the cytogenetic spectrum and clinico-hematological features of Iranian MDS patients for the first time.

## Methods

This prospective cross-sectional study was conducted on 103 patients with MDS in Ahvaz, southwest of Iran, from 2014 to 2018. Clinical presentations, complete blood counts (CBC), and bone marrow (BM) biopsy samples were assessed. Perls' staining was used to evaluate BM iron storage. The cytogenetic evaluation was performed using the conventional G banding method on the BM.

## Results

Patients' median age was 62.3 (ranged from 50–76), and the majority were male (72.8%). The most common clinical symptom at the time of admission was fatigue (n = 33) followed by pallor (n = 27). The most common subgroup was MDS-Multi Lineage Dysplasia (MDS-MLD) (n = 38, 36.8%), followed by MDS-Single Lineage Dysplasia (MDS-SLD) (n = 28, 18.4%). A normal karyotype was observed in 59 patients (57.3%), while 44 patients (42.7%) had cytogenetic abnormalities. Trisomy 8 (+8) was the most common cytogenetic abnormality (n = 14) followed by del17p (n = 9) and monosomy 7 (-7) (n = 7). Twelve patients (11.65 %) were transformed to AML.

## Conclusion

Our data betokened that among our MDS patients, Trisomy 8 is the predominant cytogenetic abnormality, and MDS-MLD and MDS-SLD are the most common of subtypes. Noteworthy, the male: female ratio was slightly higher in Iran than in previous reports from other parts of the world. Our study is the first report of the clinical, hematological, and cytogenetic spectrum of MDS patients in Iran

## Introduction

Myelodysplastic Syndromes (MDSs) are a group of hematopoietic disorders characterized by ineffective hematopoiesis, dysplasia of hematopoietic cells, and cytopenia in one or more blood cell lineages (1). MDS generally occurs *de novo*; however, a small number of MDSs are secondary to radiation and/or chemotherapy exposure. Pathophysiology of the disease includes multi-step processes involving chromosomal abnormalities and/or genetic aberrations (2). In the United States, MDS incidence is 3–4 per 100,000 annually and increases with age (3). Usually, this disease is more prevalent in men than women, except for the 5q deletion subgroup, which is more common in women (4). The disease course is very variable, ranging from an indolent to an aggressive state. However, it is often associated with an increased risk of acute myeloid leukemia (AML) transformation and a short survival rate (5). Diagnosis of MDS transpires via scrutiny of the peripheral blood smear (PBS) and the bone marrow (BM). Pancytopenia and single or multilineage dysplasia are observed in the PB, whereas less than 20% blasts and

hematopoietic cells dysplasia are detected in the BM. Based on the 2016 classification of the World Health Organization (WHO), MDS comprises six subgroups, including MDS with multilineage dysplasia (MDS-MLD), MDS with single lineage dysplasia (MDS-SLD), MDS with ring sideroblasts (MDS-RS), MDS with excess blasts (MDS-EB -1 and 2), MDS with isolated del (5q), and unclassifiable MDS (MDS-U) (6).

Cytogenetic abnormalities such as amplifications, deletions, and translocations have been detected in about 50% of patients with *de novo* MDS and 80% of patients with secondary MDS, as well (7). Evaluation of cytogenetic abnormalities is useful in the diagnosis of MDS and crucial in determining the prognosis (8). Indeed, the chromosomal abnormality type is one of the most important factors employed in the MDS Revised International Prognostic Scoring System (R-IPSS) (9). Patient prognosis helps determine the disease's clinical course and plays a vital role in establishing the patient's therapeutic plan (10).

There are many reports from western countries in terms of cytogenetic profiles of MDS patients. However, clinical symptoms, cytogenetic abnormalities, and the disease's pathophysiology are dissimilar in different populations and vary greatly in different geographic areas. Therefore, the current study aimed to determine the cytogenetic spectrum and clinico-hematological features of MDS patients in the Khuzestan province, southwest of Iran. This is the first comprehensive report from Iranian MDS patients.

## Material And Methods

### Patients and Study Design

This prospective cross-sectional study was conducted on 103 patients with MDS referred to Shafa Hospital in Ahvaz, southwest of Iran, from 2014 to 2018. Patients diagnosed as *de novo* MDS according to their clinical and hematological findings were included in the study. Notably, we excluded patients with cytopenia due to other non-malignant disorders and patients with a history of chemotherapy or radiotherapy. All patients were diagnosed and classified according to the classification of myeloid neoplasms and acute leukemia of the 2016 revision of the World Health Organization (6). This study was approved by the Ethics Committee of Ahvaz Jundishapur University of Medical Sciences. Signed consent forms were received from all the patients prior to participation in the study.

### Hematological assessments

Following the clinical examination, complete blood counts (CBC) were performed, and PBS was scrutinized. Patients suspected of having MDS were subjected to further evaluation by BM biopsy samples obtained from the posterior superior iliac spine. According to the manufacturer's protocol, assessment of Iron was performed on the BM using the Perls' stain kit (Sigma-Aldrich).

### Cytogenetic analysis

The cytogenetic evaluation was performed using a conventional G banding method on the BM samples. First, BM cells were cultured for 24 hours in 5 ml of Marrowmax medium, 20% FBS, 2 mg L-glutamine, and 100ml / U penicillin/streptomycin. Afterward, a total of 50 µl of colcemid (10 µg / ml) was added to the culture medium, and cells were incubated for 20 minutes at 37 °C. Following this, a hypotonic potassium chloride solution was added to the cells which were incubated for 25 minutes at 37 °C. Cells were then fixed with methanol:acetic acid (3:1), and slides of metaphase chromosomes were prepared in a humidified and controlled temperature environment. Metaphase chromosomes (at least 20 metaphases) were banded using the Giemsa trypsin banding (GTG) method, and karyotypes were defined according to the International System for Human Cytogenetic Nomenclature (ISCN) 2013 criteria.

# Statistical analysis

Data are displayed as mean values, while the standard error of the mean was shown using error bars (Mean  $\pm$  SEM). GraphPad Prism (Version 8.0.1.244, San Diego, CA, USA) software was utilized to perform statistical analyses.

## Results

### Patients Characteristics

Among 300 patients originally referred to the hospital, a total of 103 patients were diagnosed as *de novo* MDS according to their clinical and hematological tests and hence were included in the study. Patients' median age was 62.3 years (50- 76), and the majority of patients were of male (72.8%). The mean levels of hemoglobin (Hb), platelets (plt), and white blood cells (WBC) were 9.9g/dl,  $103 \times 10^3/\mu\text{l}$ , and  $3.4 \times 10^3/\mu\text{l}$ ; respectively (**Table 1**).

<b>Table 1.</b> Patients characteristics.		
<b>Gender</b>	Male	75 (72.81%)
	female	28 (27.19%)
<b>Age (years)</b>	Median (range)	62.3 (50-76)
<b>Work history</b>	Agriculturist	23 (22.33%)
	Petroleum worker	7 (6.79%)
	Truck driver	5 (4.85%)
	Others	68 (66%)
<b>Hemoglobin (g/dl)</b>	Mean $\pm$ SD	9.9 $\pm$ 1.1
<b>Platelet (<math>\times 10^3/\mu\text{l}</math>)</b>	Mean $\pm$ SD	103 $\pm$ 20
<b>WBC (<math>\times 10^3/\mu\text{l}</math>)</b>	Mean $\pm$ SD	3.4 $\pm$ 0.5
<b>ANC (<math>\times 10^3/\mu\text{l}</math>)</b>	Mean $\pm$ SD	1.6 $\pm$ 0.3
<b>BM cellularity</b>	Hypercellular	78 (75.73%)
	Normocellular	18 (17.47%)
	Hypocellular	7 (6.8%)
<b>BM Iron storage</b>	Increased	86 (83.5%)
	Decreased	0
	Normal	17 (16.5%)
WBC: White Blood Cells, ANC: Absolute neutrophil count, BM: Bone marrow		

More than 75% of the patients presented hypercellular BM. Moreover, iron storage was increased in 86 cases (83.5%) (**Table 1**). The major clinical symptom at the time of admission was fatigue (n=33) followed by pallor (n=27), easy

bruising and bleeding (n=20), recurrent infections (n=19), and bone pain (n=4). Finally, a total of twelve patients (11.65 %) were transformed to AML. Based on FAB classification, 4, 6, and 2 patients progressed to AML-M0, AML-M1, and AML-M2, respectively.

Subgroups	Number of patients	Normal cytogenetics	Abnormal cytogenetics
MDS-MLD	38 (36.89%)	22	16
MDS-SLD	28 (18.44%)	17	11
MDS-EB	MDS- EB-1	15 (14.56%)	11
	MDS-EB -2	11 (10.67%)	5
MDS with isolated del(5q)	4 (3.88%)	0	4
MDS-RS	3 (2.91%)	1	2
MDS-U	4 (3.88%)	3	1

MDS-MLD = MDS with multilineage dysplasia. MDS-SLD = MDS with single lineage dysplasia. MDS-EB = MDS with excess blasts. MDS-RS = MDS with ring sideroblasts. MDS-U = MDS, unclassifiable

### Patients Classification

The patients were classified into different subgroups according to the 2016 revision of the WHO classification. The most common subgroup was MDS-MLD (n=38, 36.8%) followed by MDS-SLD (n=28, 18.44%). However, the rarest subgroup was MDS-RS (n=3, 2.91%) (**Table 2**).

**Table 3.** Distribution of Cytogenetic Abnormality in MDS subgroups

<b>MDS Type</b>	<b>Abnormality</b>	<b>Number of patients</b>
<b>MDS-SLD</b>	+8	4
	dell 17p	2
	dell 17p, dell 11q	1
	dell 20q	1
	dell 20q, dell 7q	1
	-y	2
<b>MDS-MLD</b>	+8, +21, -7	1
	+8	4
	dell 17p	3
	dell 17p, +8, -7	1
	dell 20q, -y	1
	dell 20q	1
	dell 11q, +8	1
	dell 11q	1
	-y, +8	1
	-y	1
	-7	1
	<b>MDS-EB-1</b>	+8
+21		1
inv(3)(q21q26.2)		1
<b>MDS-EB-2</b>	dell 11q, dell 17p, -y	1
	dell 11q, -7	1
	+21, -7	1
	+21, dell 17p	1
	-7, dell 20q	1
	-7	1
<b>MDS with del (5q)</b>	dell 5q	4
<b>MDS-RS</b>	dell 7q	1
	+19	1
<b>MDS-U</b>	i(17q)	1

## Patients Karyotypes

Concerning the karyotypes of the patients, a total of 59 patients (57.28%) presented a normal karyotype, while the remaining 44 patients (42.72%) had cytogenetic abnormalities (**Figure 1A**). Patients with abnormal karyotype showed different types of abnormalities. Single, double and complex abnormalities were observed in 32 (72.7%), 9 (20.5%) and 3 (6.5%) patients; respectively (**Figure 1B**). The distribution of normal and abnormal karyotypes among MDS subgroups is demonstrated in **Figure 1C**. On the other hand, the most common cytogenetic abnormality among the 44 MDS patients was Trisomy 8 (+8) (n=14), followed by del17p (n=9) and monosomy 7 (-7) (n=7) (**Figure 2**). The prevalence and distribution of the chromosomal abnormalities in MDS patients are detailed in **Figure 2**. Finally, the cytogenetic profile of the studied patients is shown in **Table 3**.

## Patients Prognosis

The patients' prognosis was assessed according to the Revised International Prognostic Scoring System [R-IPSS]. Results showed that a total of 68 patients (66%) were considered as good or very good prognosis (**Table 4**). Moreover, 26 cases (25.2%) showed an intermediate prognosis. However, a poor prognosis was observed in 9 cases (8.7%), while none of the patients showed very poor prognosis (**Table 4**).

<b>Table 4.</b> Cytogenetic score groups based on R-IPSS.									
Cytogenetic prognosis subgroup	Cytogenetic abnormality	Total	MDS subtypes						
			MDS-SLD	MDS-MLD	MDS-EB-1	MDS-EB-2	MDS with del (5q)	MDS-RS	MDS-U
<b>Very good</b>	-y, del11q	3	2 (7.1%)	1 (2.6%)	0	0	0	0	0
<b>Good</b>	Normal	59	17 (60.7%)	22 (57.9%)	11 (73.3%)	5 (43.5%)	0	1 (33.3%)	3 (75%)
	del5q, del20q	6	1 (3.5%)	1 (2.6%)	0	0	4 (100%)	0	0
<b>Intermediate</b>	+8, +19, del7q, i(17q), other single/double abnormalities	26	8 (28.6%)	11 (28.9%)	3 (20%)	1 (9.1%)	0	2 (66.7%)	1 (25%)
<b>Poor</b>	-7, inv (3), double including -7/del(7q) and complex (3 abnormalities)	9	0	3 (7.9%)	1 (6.6%)	5 (45.5%)	0	0	0
<b>Very poor</b>	> 3 abnormalities	0	0	0	0	0	0	0	0

## Discussion

MDS is a heterogeneous clonal disorder associated with ineffective hematopoiesis, reduced blood cells, and hematopoietic cells' dysplasia. Generally, MDS is known as a preleukemic disorder and is considered an elderly disease. Indeed, the mean age of patients in our study was 66 years, with a range of 50–76 years, which is similar to MDS in the US population (67 years) (11), and close to Turkey (69 years) (12) and European countries such as Germany (70 years) (13) and Poland (14) (70 years). On the other hand, our results are significantly different from those of East Asian countries such as China (49 years) (15), India (42, 45, and 55 years) (16–18), and Japan (76 years) (19). Most of the patients were farmers or worked in petroleum jobs. It is worth noting that most of the farmers in the southwest regions of Iran, where our study was conducted, are exposed to pesticides. The association of pesticide exposure and MDS incidence was recently confirmed in a meta-analysis study (20). Moreover, many investigators reported that petroleum workers exposed to benzene had an important MDS risk factor (21, 22). The male to female ratio was 2.6:1, which was clearly higher than those reported from the US (1.9: 1) (11), Korea (1.7: 1) (23), China (1.3: 1) (15), and Pakistan (1.7: 1) (24). In Iranian culture, women do not work as much as men, especially the high-risk jobs, which might explain the higher male: female ratio in our study compared to other reports.

The mean hemoglobin level in our study on southwest Iranian patients was 9.9 g / dl, which is similar to that obtained in Turkey (9 g / dl) (12) and Greece (9.5 g / dl) (25). However, our hemoglobin data are higher than those obtained in Pakistan (7.7 g / dl), China (6.3 g / dl) (15), Singapore (7.7 g / dl) (26), and India (6.84 g / dl) (18). The difference may be due to the higher percentage of males in our study and the fact that Iran implements a national iron supplementation program. On the other hand, the mean platelet counts in our study was  $103 \times 10^3 / \mu\text{l}$ , which is similar to those obtained by Lau *et al.* in Singapore ( $101 \times 10^3 / \mu\text{l}$ ) (26). However, our data on platelets counts are higher than those obtained by Chen *et al.* in China ( $42 \times 10^3 / \mu\text{l}$ ) (15), Ehsan *et al.* in Pakistan ( $60 \times 10^3 / \mu\text{l}$ ), and Chaubey *et al.* in India ( $85 \times 10^3 / \mu\text{l}$ ) (18). Noteworthy that even higher platelet counts were reported in Turkey ( $163 \times 10^3 / \mu\text{l}$ ) (12) and Greece ( $158 \times 10^3 / \mu\text{l}$ ) (25).

Although our study included patients from the 2014 to 2018 period, all patients were re-classified according to the 2016 revision of the World Health Organization classification of myeloid neoplasms and acute leukemia (6). Our data showed that the most common MDS subgroup was MDS-MLD (36.9%), followed by MDS-SLD (18.4%). These results are in line with those of Haase *et al.* in Germany (27) and Rashid *et al.* in Pakistan (28), who reported that MDS-MLD is the most common subtype (27.6% and 52.1%, respectively). Moreover, Pozdnyakova *et al.* in the USA (11) and Li *et al.* in China (29) reported that MDS-MLD was the most common subgroup (Respectively 32.2% and 44%) followed by MDS-EB-I. In contrast, Chauby *et al.* reported MDS-SLD as the most common type of MDS in India (18). The aforementioned differences might be due to the different ethnicity, population of the study, and/or sensitivity of the applied laboratory assay.

Cytogenetic abnormalities play a substantial role in the pathogenesis of MDS and are key factors in the diagnosis, classification, and prognostic scoring of the disease. However, the pathogenesis of MDS is still not well understood in Iran. The environmental, occupational, and genetic factors in Iran's southwest region are very different from western countries. This would affect the pathogenesis of MDS and may cause various chromosomal abnormalities, different frequencies, and patterns of MDS subtypes. Chromosomal abnormalities were observed in 42.7% of the patients, in accordance to other studies conducted in different parts of the world such as in Pakistan (42.3%) (28), the United States (44.5%) (11), Germany (49.8%) (27), Tunisia (51%) (30), and India (47.5%) (18). However, this was less than what was found in China (67.5%) (29). Among patients with abnormal karyotypes, 72.7% had a single abnormality, 20.5% had double abnormalities, while 6.8% had complex abnormalities (more than 3 abnormalities). The prognostic score of the studied patients was assessed according to R-IPSS. Accordingly, more than 91.3% of patients had very

good, good, and intermediate prognosis. However, the poor prognosis was observed in only 9 cases, and very poor prognosis was observed in none of the patients.

In this study, the most common chromosomal abnormality was trisomy 8 (13.6% of all patients and 31.8% of patients with abnormal karyotype), followed by del 17p (8.7% of all patients and 20.5% of patients with abnormal karyotype). Trisomy 8 was observed in 10 patients as a single chromosomal abnormality, in 2 patients with double chromosomal abnormalities, and in 2 patients with a complex karyotype. In accordance, Li *et al.* in China (29) and Rashid *et al.* in Pakistan (28) showed that the most common chromosomal abnormality was trisomy 8. In contrast, the most common chromosomal abnormality in Tunisia (30), Germany (27), Switzerland (31), Greece (25), and the United States (11) was - 5 / del (5q). Our results showed that chromosomal abnormalities in Iranian MDS patients often include changes in the copy number (except for 2 cases), including deletion of all or part of a chromosome (e.g., del 17p or monosomy 7) or gain of a chromosome (e.g., trisomy 8), while balance abnormalities (such as translocations) have a very low incidence in patients. The changes in copy numbers result in a change in the dosage of genes, which can lead to the inactivation of tumor suppressor genes and the activation of oncogenes by various mechanisms such as haploinsufficiency and loss of heterozygosity, thus playing an essential role in the initiation and progression of the disease. For instance, it has been shown that the CUX1 gene, expressed on chromosome 7, acts as a tumor suppressor gene in myeloid precursors, decreases in MDS (and AML) with - 7 / del (7q), and is involved in the pathogenesis of the disease (32). It is worth noting that MDS cells with trisomy 8 (+ 8) express high levels of antiapoptotic proteins and have high resistance to apoptotic agents, such as gamma rays (33).

There has not been such a registry developed to capture the MDS epidemiology in Iran yet. So, we will be the pioneer to report the Clinico-Hematological and cytogenetic spectrum of adult myelodysplastic syndrome in addition to the plethora of scientific information that is already available in the western and eastern literature.

## Conclusion

Our data indicated that MDS-MLD and MDS-SLD are the most common subtypes of MDS in Iran's southwest region. In addition, Trisomy 8 was the most predominant cytogenetic abnormality. Moreover, our results showcased that the male: female ratio is slightly higher than previous reports from other parts of the world. This study represents the first report of the clinical, hematological, and cytogenetic spectrum of MDS patients in Iran. This study's major limitations are that patients' overall survival, treatment strategies, and response to treatment were not evaluated and suggested to be resolved in future studies.

## Abbreviations

Myelodysplastic syndrome (MDS)

Complete blood counts (CBC)

Bone marrow (BM)

Acute myeloid leukemia (AML)

Peripheral blood smear (PBS)

World Health Organization (WHO)

MDS-Multi Lineage Dysplasia (MDS-MLD)

MDS-Single Lineage Dysplasia (MDS-SLD)

MDS with ring sideroblasts (MDS-RS)

MDS with excess blasts (MDS-EB)

Unclassifiable MDS (MDS-U)

Revised International Prognostic Scoring System (R-IPSS)

Giemsa trypsin banding (GTG)

International System for Human Cytogenetic Nomenclature (ISCN)

## **Declarations**

### **Ethics approval and consent to participate**

All procedures have been approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

### **Consent for publication**

Informed consent was signed prior to participation in the study.

### **Availability of data and materials**

The datasets used and analyzed during this study are available from the corresponding author on reasonable request.

### **Competing interests**

The authors declared no conflict of interest.

### **Funding**

Not available

### **Authors contribution**

Omid Kiani Ghalesardi designed the study. Mostafa Paridar, Omid Kiani Ghalesardi, Abbas Khosravi, Seyed Esmaeil Ahmadi, Maral Soleymani, and Ebrahim Azizi carried out the experiments. Kazem Zibara analyzed the data. Mostafa Paridar and Kazem Zibara wrote the paper. Seyed Esmaeil Ahmadi validated and edited the paper. All authors discussed the results and commented on the manuscript.

### **Acknowledgements**

We wish to thank all our colleagues in Shafa Hospital, Ahvaz, Iran.


## **References**

1. Shahrabi S, Khosravi A, Shahjahani M, Rahim F, Saki N. Genetics and Epigenetics of Myelodysplastic Syndromes and Response to Drug Therapy: New Insights. *Oncol Rev.* 2016;10(2):311-.

2. Shallis RM, Ahmad R, Zeidan AM. The genetic and molecular pathogenesis of myelodysplastic syndromes. *Eur J Haematol.* 2018;101(3):260–71.
3. Goldberg SL, Chen E, Corral M, Guo A, Mody-Patel N, Pecora AL, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology.* 2010;28(17):2847–52.
4. Ma X. Epidemiology of myelodysplastic syndromes. *Am J Med.* 2012;125(7 Suppl):2–5.
5. Montalban-Bravo G, Garcia-Manero G. Myelodysplastic syndromes. 2018 update on diagnosis, risk-stratification and management. *Am J Hematol.* 2018;93(1):129–47.
6. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood.* 2016;127(20):2391–405.
7. Paridar M, Ghalesardi OK, Seghatoleslami M, Ahmadzadeh A, Khosravi A, Saki N. Cytogenetic and molecular basis of BCR-ABL myelodysplastic syndrome: diagnosis and prognostic approach. *Journal of Cancer Metastasis Treatment.* 2017;3(2):38–44.
8. Ghale-sardi OK, JalaliFar MA, Khodadi E, Ahmadzadeh A, Saki N. BCR/ABL analysis in myelodysplastic syndromes. *Comp Clin Pathol.* 2018;27(2):379–84.
9. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. *Blood.* 2012;120(12):2454–65.
10. Steensma DP. Myelodysplastic syndromes current treatment algorithm 2018. *Blood cancer journal.* 2018;8(5):47.
11. Pozdnyakova O, Miron PM, Tang G, Walter O, Raza A, Woda B, et al. Cytogenetic abnormalities in a series of 1,029 patients with primary myelodysplastic syndromes: a report from the US with a focus on some undefined single chromosomal abnormalities. *Cancer.* 2008;113(12):3331–40.
12. Demirkan F, Alacacioglu I, Piskin O, Ozsan HG, Akinci B, Ozcan AM, et al. The clinical, haematological and morphological profile of patients with myelodysplastic syndromes: a single institution experience from Turkey. *Leuk Lymphoma.* 2007;48(7):1372–8.
13. Gattermann N, Kundgen A, Kellermann L, Zeffel M, Paessens B, Germing U. Diagnosis and therapy of myelodysplastic syndromes in Germany: a retrospective multicenter analysis. *Onkologie.* 2012;35(6):350–6.
14. Madry K, Machowicz R, Waszczuk-Gajda A, Drozd-Sokolowska J, Holowiecka BS, Wiater E, et al. Demographic, Hematologic, and Clinical Features of Myelodysplastic Syndrome Patients: Results from the First Polish Myelodysplastic Syndrome Registry. *Acta haematologica.* 2015;134(2):125–34.
15. Chen B, Zhao WL, Jin J, Xue YQ, Cheng X, Chen XT, et al. Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries. *Leukemia.* 2005;19(5):767–75.
16. Chatterjee T, Dixit A, Mohapatra M, Tyagi S, Gupta PK, Mishra P, et al. Clinical, haematological and histomorphological profile of adult myelodysplastic syndrome. Study of 96 cases in a single institute. *Eur J Haematol.* 2004;73(2):93–7.
17. Dakshinamurthy AG, Novitzky N, Bharadwaj R, Prakhya BM. Cytogenetic analysis of 52 Indian patients with de novo myelodysplastic syndromes—a comparative analysis of results with reports from Asia. *Annals of hematology.* 2005;84(5):298–303.
18. Chaubey R, Sazawal S, Dada R, Mahapatra M, Saxena R. Cytogenetic profile of Indian patients with de novo myelodysplastic syndromes. *Indian J Med Res.* 2011;134:452–7.
19. Chihara D, Ito H, Katanoda K, Shibata A, Matsuda T, Sobue T, et al. Incidence of myelodysplastic syndrome in Japan. *Journal of epidemiology.* 2014;24(6):469–73.

20. Jin J, Yu M, Hu C, Ye L, Xie L, Jin J, et al. Pesticide exposure as a risk factor for myelodysplastic syndromes: a meta-analysis based on 1,942 cases and 5,359 controls. *PloS one*. 2014;9(10):e110850.
21. Khalade A, Jaakkola MS, Pukkala E, Jaakkola JJ. Exposure to benzene at work and the risk of leukemia: a systematic review and meta-analysis. *Environ Health*. 2010;9(1):31.
22. Schnatter AR, Glass DC, Tang G, Irons RD, Rushton L. Myelodysplastic syndrome and benzene exposure among petroleum workers: an international pooled analysis. *J Natl Cancer Inst*. 2012;104(22):1724–37.
23. Lee JH, Lee JH, Shin YR, Lee JS, Kim WK, Chi HS, et al. Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome. *Leukemia*. 2003;17(2):305–13.
24. Sultan S, Irfan SM. Adult Primary Myelodysplastic Syndrome: Experience from a Tertiary Care Center in Pakistan. *Asian Pacific journal of cancer prevention: APJCP*. 2016;17(3):1535–7.
25. Avgerinou C, Alamanos Y, Zikos P, Lampropoulou P, Melachrinou M, Labropoulou V, et al. The incidence of myelodysplastic syndromes in Western Greece is increasing. *Ann Hematol*. 2013;92(7):877–87.
26. Lau LG, Chng WJ, Liu TC, Tan LK, Ong KH, Mow BM, et al. Clinico-pathological analysis of myelodysplastic syndromes according to French-American-British classification and international prognostic scoring system. *Ann Acad Med Singapore*. 2004;33(5):589–95.
27. Haase D, Germing U, Schanz J, Pfeilstocker M, Nosslinger T, Hildebrandt B, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. *Blood*. 2007;110(13):4385–95.
28. Rashid A, Khurshid M, Shaikh U, Adil S. Chromosomal abnormalities in primary myelodysplastic syndrome. *Journal of the College of Physicians Surgeons–Pakistan: JCPSP*. 2014;24(9):632–5.
29. Li L, Liu XP, Nie L, Yu MH, Zhang Y, Qin TJ, et al. Unique cytogenetic features of primary myelodysplastic syndromes in Chinese patients. *Leukemia research*. 2009;33(9):1194–8.
30. Gmidene A, Sennana H, Fenaux P, Laatiri A, Zarrouk M, Bouaziz H, et al. Cytogenetic abnormalities in Tunisian de novo myelodysplastic syndrome: a comparison with other populations. *Leukemia research*. 2008;32(12):1824–9.
31. Parlier V, van Melle G, Beris P, Schmidt PM, Tobler A, Haller E, et al. Hematologic, clinical, and cytogenetic analysis in 109 patients with primary myelodysplastic syndrome. Prognostic significance of morphology and chromosome findings. *Cancer Genet Cytogenet*. 1994;78(2):219–31.
32. Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. *Blood*. 2013;122(22):3616–27. quiz 99.
33. Sloand EM, Pfannes L, Chen G, Shah S, Solomou EE, Barrett J, et al. CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins. *Blood*. 2007;109(6):2399–405.

## Figures



**Figure 1**

Prevalence of the cytogenetic abnormalities observed in MDS patients. A: Prevalence of normal and abnormal karyotypes among MDS patients. B: Types of abnormalities among patients with abnormal karyotype. C: Distribution of normal and abnormal karyotypes among MDS subgroups.




Figure 2

The prevalence of chromosomal abnormalities in MDS patients.